Blue Ear Drum as an Unusual Adverse Effect of Adalimumab: A Case Report
Abstract
Adalimumab has been employed for an extended period as an efficacious and secure agent for inflammatory bowel and rheumatic diseases. ABP 501 is one of the biosimilars of adalimumab and has a similar safety profile to that of the original adalimumab. This report presents the first documented case of a 42-year-old female with Crohn’s disease and ankylosing spondylitis who developed hemotympanum following administration of adalimumab biosimilar (ABP 501), resulting in a blue ear drum. Following the discontinuation of adalimumab, the patient demonstrated recovery with the administration of oral (levofloxacin, dexketoprofen) and topical (ciprofloxacin, dexamethasone) therapy. This case suggests that adalimumab may be associated with the development of hemotympanum, which presents as a blue ear drum.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.